The Oncology Institute, Inc. TOI Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s derivative, gain (loss) on derivative, net?
- The Oncology Institute, Inc. (TOI) reported derivative, gain (loss) on derivative, net of $5M in Q1 2026.
- How has The Oncology Institute, Inc.'s derivative, gain (loss) on derivative, net changed year-over-year?
- The Oncology Institute, Inc.'s derivative, gain (loss) on derivative, net increased by 251.0% year-over-year, from -$3.31M to $5M.
- What does derivative, gain (loss) on derivative, net mean?
- This metric captures the net realized and unrealized gains or losses arising from derivative financial instruments used by the company. These instruments are typically employed for hedging purposes or as part of complex financing arrangements to manage market risks. Analyzing this line item helps stakeholders understand the impact of financial risk management activities on the company's bottom-line profitability.